Merck Manual

Please confirm that you are a health care professional

Loading

Legionella Infections

(Legionnaires' Disease)

By

Larry M. Bush

, MD, FACP, Charles E. Schmidt College of Medicine, Florida Atlantic University;


Maria T. Vazquez-Pertejo

, MD, Wellington Regional Medical Center

Last full review/revision Feb 2020| Content last modified Feb 2020
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Topic Resources

Legionella pneumophila is a gram-negative bacillus that most often causes pneumonia with extrapulmonary features. Diagnosis requires specific growth media, serologic or urine antigen testing, or polymerase chain reaction analysis. Treatment is with macrolides, fluoroquinolones, or doxycycline.

Legionella pneumophila was first recognized in 1976 after an outbreak at a convention of the American Legion in Philadelphia, Pennsylvania—thus, the name legionnaires’ disease. This disease is the pneumonic form of an infection usually caused by Legionella pneumophila serogroup 1. Nonpneumonic infection is called Pontiac fever, which manifests as a febrile, viral-like illness.

Transmission of Legionella species

Legionella organisms are often present in soil and fresh water. Amebas present in fresh water are a natural reservoir for these bacteria. Legionella organisms may enter a building's plumbing system via freshwater sources; a building’s water supply is often the source of a Legionella outbreak. Legionella organisms are embedded in a biofilm that forms on the inside of water pipes and containers. The infection is usually acquired by inhaling aerosols (or less often aspiration) of contaminated water (eg, as generated by shower heads, misters, whirlpool baths, or water cooling towers for air-conditioning). Nosocomial infection usually involves a contaminated hot water supply.

Legionella infection is not transmitted from person to person, although one probable case was reported in 2016.

Diseases caused by Legionella species

Legionella infection is more frequent and more severe in the following:

  • Older people

  • Patients with diabetes or chronic obstructive pulmonary disease (COPD)

  • Cigarette smokers

  • Immunocompromised patients (typically with diminished cell-mediated immunity)

The lungs are the most common site of infection; community- and hospital-acquired pneumonia may occur.

Extrapulmonary legionellosis is rare; manifestations include sinusitis, hip wound infection, myocarditis, pericarditis, and prosthetic valve endocarditis, frequently in the absence of pneumonia.

Symptoms and Signs

Legionnaires’ disease is a flu-like syndrome with acute fever, chills, malaise, myalgias, headache, or confusion. Nausea, loose stools or watery diarrhea, abdominal pain, cough, and arthralgias also frequently occur. Pneumonic manifestations may include dyspnea, pleuritic pain, and hemoptysis. Bradycardia relative to fever may occur, especially in severe cases.

Overall mortality is low (about 5%) but can reach 40% in patients with hospital-acquired infections, older people, and immunocompromised patients.

Diagnosis

  • Direct fluorescent antibody staining

  • Sputum culture using specific growth media

  • Rapid urinary antigen test (for serogroup 1 only)

Direct fluorescent antibody staining of sputum or bronchoalveolar lavage fluid is occasionally used but requires expertise. In addition, polymerase chain reaction testing with DNA probing is available and may help identify transmission pathways. A urinary antigen test is 60 to 95% sensitive and > 99% specific 3 days after symptom onset but detects only L. pneumophila (serogroup 1), which accounts for up to 80% of cases (1). Paired acute and convalescent antibody assays may yield a delayed diagnosis. A 4-fold increase or an acute titer of 1:128 is considered diagnostic.

Diagnosis of legionnaires' disease is by culture of sputum or bronchoalveolar lavage fluid; blood cultures are unreliable. Specific growth media are required. Slow growth on laboratory media may delay identification for 3 to 5 days.

Chest x-ray should be done; it usually shows patchy and rapidly asymmetrically progressive infiltrates (even when effective antibiotic therapy is used), with or without small pleural effusions.

Laboratory abnormalities often include hyponatremia, hypophosphatemia, and elevated aminotransferase levels and C-reactive protein.

Diagnosis reference

Treatment

  • Fluoroquinolones

  • Macrolides (preferably azithromycin)

  • Sometimes doxycycline

A fluoroquinolone given IV or orally for 7 to 14 days and, for severely immunocompromised patients, sometimes up to 3 weeks is the preferred regimen. Azithromycin (for 5 to 10 days) is effective, but erythromycin may be less effective. Erythromycin should be used only for mild pneumonia in patients who are not immunocompromised. Doxycycline is an alternative for immunocompetent patients with mild pneumonia.

The addition of rifampin is no longer recommended because benefit has not been proved and there is potential for harm.

Key Points

  • L. pneumophila usually causes pulmonary infection; it rarely causes extrapulmonary infections (most often involving the heart).

  • L. pneumophila infection is typically acquired by inhaling aerosols (or less often by aspiration) of contaminated water; it is not transmitted from person to person.

  • Diagnose using direct fluorescent antibody staining or polymerase chain reaction testing; sputum cultures are accurate but may take 3 to 5 days.

  • Treat using a fluoroquinolone or azithromycin; doxycycline is an alternative.

More Information

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Videos

View All
Overview of Lyme Disease
Video
Overview of Lyme Disease
3D Models
View All
SARS-CoV-2
3D Model
SARS-CoV-2

SOCIAL MEDIA

TOP